We have partnered with Clerio Vision

Developers of Laser Induced Refractive Index Correction (LIRIC) technology

Effective July 2019, Extreme H2O is part of Clerio Vision – developers of a revolutionary ophthalmic product platform based on a femtosecond laser technology.  The long standing expertise of Extreme H2O manufacturing, and distribution of specialty high performance contact lenses, was a perfect fit for Clerio’s mission:

To deliver ground breaking solutions to the millions of patients requiring vision correction

Clerio Vision has developed a Laser Induced Refractive Index Correction (LIRIC) technology that enables the writing of unique patterns into contact lenses that optimize visual acuity, including superior correction at both far and near distances for those with presbyopia.  A multifocal contact lens is currently in clinical development and is expected to be on the market within the next 18 months. Click here to be notified on product updates. 


The Extreme H2O product line caters to your specific practice needs and provides you with lens fitting solutions you can’t get elsewhere. We are committed to offering superior and innovative products with differentiated materials, fitting options, and packaging — all designed to exceed patient expectations and enhance practice profitability.

All Extreme H2O products are made with the purist form of Hioxifilcon A & D – non-ionic, ultra-hydrating materials that retain up to 99% of their moisture.  This keeps eyes fresh and hydrated all day long.

Made in the USA.  We are located in Sarasota, Florida where all of our products are made in our highly automated manufacturing facility. 


Clerio Vision is developing a innovative product platform for the global ophthalmic market based on technology licensed from the University of Rochester.  They are in the process of developing and commercializing a portfolio of next generation products in contact lenses, refractive surgery, and the cataract market. The company has raised approximately $30 million in financing from Safar Partners, Stonehenge Growth Equity, Armory Square Ventures, prominent angel investors and the National Science Foundation.